
TABLE OF CONTENTS

Sr. No.	Contents	Page No.
A	List of Tables	VII
B	List of Figures	X
C	List of Materials	XIII
D	List of Instruments/ Equipments	XV
E	Abbreviations	XVI
F	Abstract	XIX
CHAPTER 1: INTRODUCTION		
1.1	INTRODUCTION	3
1.2	AIMS & OBJECTIVES	10
1.3	PLAN OF WORK	10
	REFERENCES	11
CHAPTER 2: LITERATURE REVIEW		
2.1	CANCER	18
2.2	BREAST CANCER	18
2.2.1	Treatment for Breast Cancer	19
2.2.2	Classification of Chemotherapy	21
2.2.3	Drug Resistance – A challenge in Breast Cancer	23
2.2.4	Review of Drug Combinations used in Cancers	25
2.3	NANOSTRUCTURED LIPID CARRIERS (NLCS)	30
2.3.1	Classification of NLCs	30
2.3.2	Method of Preparation	32
2.4	MICROEMULSIONS (ME)	37
2.4.1	Classification of Microemulsions	37
2.4.2	Method of Preparation	40
2.5	DRUG PROFILE	43
2.5.1	PACLITAXEL	43
2.5.2	CYCLOPHOSPHAMIDE	46
	REFERENCES	49
CHAPTER 3: ANALYTICAL METHODS		
3.1	METHOD OF ESTIMATION OF PACLITAXEL BY RP-HPLC	67

Sr. No.	Contents	Page No.
3.2	METHOD OF ESTIMATION OF CYCLOPHOSPHAMIDE BY RP-HPLC	68
3.3	VERIFICATION OF METHODS	69
3.3.1	Verification of HPLC method for determination of Paclitaxel	70
3.3.2	Verification of HPLC method for determination of Cyclophosphamide	75
REFERENCES		81
CHAPTER 4: PREFORMULATION STUDIES		
4.1	AUTHENTICATION OF ACTIVE INGREDIENTS	84
4.1.1	Melting Point Determination	84
4.1.2	FTIR Spectroscopy	84
4.1.3	Determination of Wavelength Maxima	84
4.2	SCREENING OF SOLID LIPIDS	85
4.3	SCREENING OF LIQUID LIPIDS/ OILS	85
4.4	SCREENING OF CO-SURFACTANTS	85
4.5	SOLID LIPID-LIQUID LIPID COMPATIBILITY STUDIES	85
4.6	SELECTION OF CO-SOLVENT	86
4.7	DRUG EXCIPIENT COMPATIBILITY STUDIES	86
RESULTS AND DISCUSSION		87
4.8	AUTHENTICATION OF ACTIVE INGREDIENTS	87
4.8.1	Melting Point Determination	87
4.8.2	FTIR Spectroscopy	87
4.8.3	Determination of Wavelength Maxima	88
4.9	SCREENING OF SOLID LIPIDS	89
4.10	SCREENING OF LIQUID LIPIDS/ OILS	90
4.11	SCREENING OF CO-SURFACTANTS	91
4.12	SOLID LIPID-LIQUID LIPID COMPATIBILITY STUDIES	91
4.13	DRUG EXCIPIENT COMPATIBILITY STUDIES	91
REFERENCES		95
CHAPTER 5: FORMULATION DEVELOPMENT - NLCs		
5.1	METHOD FOR NLCS MANUFACTURING	103
5.2	OPTIMIZATION OF FORMULATION AND PROCESS PARAMETERS	113

Sr. No.	Contents	Page No.
5.3	LYOPHILIZATION OF NLCs	114
5.3.1	Selection of Cryoprotectant	114
5.3.2	Freeze Drying Microscopy	114
5.3.3	SMART TM Lyophilization Cycle Development	115
5.4	CHARACTERIZATION OF PAC-CYC NLCs	116
5.4.1	Description, Redispersibility and Reconstitution of Lyophilized NLCs	116
5.4.2	Particle size distribution and Zeta Potential	116
5.4.3	Assay of Paclitaxel	117
5.4.4	Assay of Cyclophosphamide	117
5.4.5	Entrapment efficiency	117
5.4.6	Water content	118
5.4.7	FTIR Spectroscopy	118
5.4.8	Differential Scanning Calorimetry	118
5.4.9	X-ray Diffraction study	118
5.4.10	Morphology by Transmission Electron Microscopy	119
5.4.11	In-Vitro release studies	119
5.4.12	Filterability	119
5.4.13	Sterility	120
5.5	STABILITY STUDIES	120
RESULTS AND DISCUSSION		121
5.6	OPTIMIZATION OF FORMULATION PARAMETERS	121
5.6.1	Selection of Surfactants	121
5.6.2	Optimization of total lipid concentration	123
5.6.3	Ratio of Solid lipid to liquid lipid	125
5.6.4	Drug substance concentration	126
5.7	OPTIMIZATION OF PROCESS PARAMETERS	128
5.7.1	Optimization of Mixing Speed	128
5.7.2	Optimization of mixing time	128
5.7.3	Optimization of temperature of Phases	129
5.8	LYOPHILIZATION OF NLCs	131
5.8.1	Selection of Cryoprotectants	131

Sr. No.	Contents	Page No.
5.8.2	Freeze Drying Microscopy	134
5.8.3	SMART™ Lyophilization cycle Development	135
5.9	CHARACTERIZATION OF LYOPHILIZED NLCs	140
5.9.1	Description, Redispersibility and Reconstitution of Lyophilized NLCs	140
5.9.2	Particle size distribution and zeta potential	140
5.9.3	Entrapment efficiency, Assay of Paclitaxel, and Assay of Cyclophosphamide	142
5.9.4	Water content	143
5.9.5	FTIR Spectroscopy	143
5.9.6	Differential scanning calorimetry	145
5.9.7	X-Ray Diffraction study	147
5.9.8	Morphology by Transmission Electron Microscopy	149
5.9.9	In-vitro release study	150
5.9.10	Sterility	152
5.10	STABILITY STUDIES	153
	REFERENCES	157
CHAPTER 6: FORMULATION DEVELOPMENT – MICROEMULSION (MEs)		
6.1	METHOD FOR MICROEMULSION MANUFACTURING	179
6.2	OPTIMIZATION OF FORMULATION PARAMETERS	188
6.2.1	Screening of Surfactants	188
6.2.2	Optimization of Surfactant: Co-surfactant (S_{mix}) ratio	188
6.2.3	Optimization of Drug Substance Concentration	189
6.2.4	Optimization of Oil and S_{mix}	190
6.3	OPTIMIZATION OF PROCESS PARAMETERS	191
6.4	CHARACTERIZATION OF MICROEMULSION	191
6.4.1	Dilution test	191
6.4.2	Viscosity	191
6.4.3	Globule size distribution and Zeta Potential	191
6.4.4	Morphology by Transmission Electron Microscopy	192
6.4.5	Assay of Paclitaxel	192
6.4.6	Assay of Cyclophosphamide	192
6.4.7	Entrapment efficiency	192

Sr. No.	Contents	Page No.
6.4.8	In-Vitro release studies	193
6.4.9	% Filterability	193
6.4.10	Sterility	194
6.5	STABILITY STUDIES	194
RESULTS & DISCUSSION		195
6.6	OPTIMIZATION OF PRODUCT PARAMETERS	195
6.6.1	Screening of Surfactants	195
6.6.2	Optimization of Surfactant: Co-surfactant ratio	197
6.6.3	Optimization of Drug Substance Concentration	199
6.6.4	Optimization of Oil and Smix	200
6.7	OPTIMIZATION OF PROCESS PARAMETERS	201
6.8	CHARACTERIZATION OF MICROEMULSION	203
6.8.1	Dilution test	203
6.8.2	Viscosity	203
6.8.3	Zeta Potential	204
6.8.4	Globule size distribution	205
6.8.5	Morphology by TEM	205
6.8.6	Entrapment efficiency, Assay of Paclitaxel, and Assay of Cyclophosphamide	206
6.8.7	In-vitro drug release study	206
6.8.8	Sterility	208
6.9	STABILITY STUDIES	209
REFERENCES		213
CHAPTER 7: IN-VITRO CELL LINE & IN-VIVO EFFICACY STUDIES		
7.1	DETERMINATION OF SYNERGISM	229
7.1.1	Methodology	229
7.1.2	Results and Discussion	230
7.2	CELL VIABILITY ASSAY	231
7.2.1	Methodology	231
7.2.2	Results and Discussion	232
7.3	CELLULAR UPTAKE AND CELL APOPTOSIS BY FLUORESCENCE MICROSCOPY	236

Sr. No.	Contents	Page No.
7.3.1	Methodology	236
7.3.2	Results and Discussion	237
7.4	CELL CYCLE ANALYSIS BY FLOW CYTOMETRY	239
7.4.1	Methodology	239
7.4.2	Results and Discussion	239
7.5	IN-VIVO EFFICACY STUDY	242
7.5.1	Methodology	242
7.5.2	Results and Discussion	243
REFERENCES		252
SUMMARY AND CONCLUSIONS		
SUMMARY		262
CONCLUSIONS		269
ANNEXURES		
Annexure – A: List of Publications & Patents		271
Annexure – B: Plagiarism Certificate		273
